Verici Dx plc (AIM: VRCI)
6.55
-0.20 (-2.95%)
Sep 11, 2024, 1:43 PM GMT+1
Verici Dx Company Description
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients.
Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.
The company was incorporated in 2020 and is based in Cardiff, the United Kingdom.
Verici Dx plc
Country | United Kingdom |
Founded | 2020 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 14 |
CEO | Sara Barrington |
Contact Details
Address: Avon House Cardiff, CF64 2EZ United Kingdom | |
Website | vericidx.com |
Stock Details
Ticker Symbol | VRCI |
Exchange | London Stock Exchange AIM |
Fiscal Year | January - December |
Reporting Currency | USD |
ISIN Number | GB00BM8HZD43 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Sara Barrington | Chief Executive Officer |
David Anderson | Chief Financial Officer |